7 April 2016Americas

DLA Piper adds partner and chair of FDA group

Law firm DLA Piper has hired James Czaban as a partner in the firm’s government affairs practice and chair of the firm’s US Food and Drug Administration group in Washington, DC.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

More on this story

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

More on this story

DLA Piper recruits life sciences lawyer for Silicon Valley

29 July 2014 DLA Piper has appointed life sciences lawyer Shane Albright to its corporate and finance practice.

FDA clears orphan drug backlog

14 September 2017 The Food and Drugs Administration has cleared the backlog of orphan drug designation requests, one month early.

article

Why you shouldn’t overlook Canadian IP litigation

2 October 2017 Canada has a robust and reliable framework for resolving IP disputes, and it shouldn’t be ignored by litigants, say Ron Dimock, Sangeetha Punniyamoorthy and Nikolas Purcell of DLA Piper.

More features

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York

UPC deals further blow to Dexcom in glucose monitor dispute with Abbott

‘A marathon and a sprint at the same time’: How we won $452m damages